Nifty
:
25637.80
Sensex
:
84058.90
88.80 (0.35%)
303.03 (0.36%)
Nifty
Sensex
:
:
25637.80
84058.90
88.80 (0.35%)
303.03 (0.36%)

Sun Pharmaceutical Industries Ltd.

Pharmaceuticals & Drugs - Global

Rating :
63/99

BSE: 524715 | NSE: SUNPHARMA

NSE BSE
1687.60
27-Jun-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1670.2
  •  1695.7
  •  1668.2
  •  1669.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  5313904
  •  8945559886.4
  •  1960.35
  •  1498.3

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 4,05,007.74
  • 37.06
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 3,95,545.75
  • 0.95%
  • 5.61

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.48%
  • 2.08%
  • 5.42%
  • FII
  • DII
  • Others
  • 17.96%
  • 17.17%
  • 2.89%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.88
  • 8.11
  • 7.85

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.07
  • 12.82
  • 5.23

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.76
  • 20.53
  • 42.98

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 38.98
  • 40.41
  • 39.97

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.95
  • 4.55
  • 5.25

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.99
  • 20.94
  • 23.09

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
39.9
45.6
52.14
59.05
P/E Ratio
42.30
37.01
32.37
28.58
Revenue
47758
52041
57444
63114
EBITDA
12987
15086
15995
18055
Net Income
9576
10929
12543
14215
ROA
11.5
12.3
12
12.9
P/B Ratio
17.09
5.61
4.98
4.40
ROE
16.01
16.09
16.4
16.55
FCFF
10426
12589
9716
12271
FCFF Yield
2.76
3.34
2.57
3.25
Net Debt
-15832
-22626
-27853
-36929
BVPS
98.75
301
339.09
383.24

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
12,958.84
11,982.90
8.14%
13,675.46
12,380.70
10.46%
13,291.39
12,192.41
9.01%
12,652.75
11,940.84
5.96%
Expenses
9,533.99
8,947.75
6.55%
9,666.44
9,028.43
7.07%
9,480.52
9,013.03
5.19%
9,045.13
8,611.11
5.04%
EBITDA
3,424.85
3,035.15
12.84%
4,009.02
3,352.27
19.59%
3,810.87
3,179.38
19.86%
3,607.62
3,329.73
8.35%
EBIDTM
26.43%
25.33%
29.32%
27.08%
28.67%
26.08%
28.51%
27.89%
Other Income
904.11
605.94
49.21%
465.62
374.76
24.24%
482.09
293.61
64.19%
532.55
206.48
157.92%
Interest
49.14
73.57
-33.21%
51.51
34.73
48.32%
69.17
49.29
40.33%
61.54
80.88
-23.91%
Depreciation
663.79
650.36
2.07%
630.56
622.14
1.35%
625.91
632.82
-1.09%
655.13
651.32
0.58%
PBT
3,254.35
2,815.52
15.59%
3,476.40
3,000.35
15.87%
3,597.88
2,790.88
28.92%
3,423.50
2,481.14
37.98%
Tax
1,093.71
148.93
634.38%
558.86
432.32
29.27%
567.21
390.10
45.40%
552.25
468.10
17.98%
PAT
2,160.64
2,666.59
-18.97%
2,917.54
2,568.03
13.61%
3,030.67
2,400.78
26.24%
2,871.25
2,013.04
42.63%
PATM
16.67%
22.25%
21.33%
20.74%
22.80%
19.69%
22.69%
16.86%
EPS
8.96
11.06
-18.99%
12.10
10.52
15.02%
12.67
9.90
27.98%
11.82
8.43
40.21%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
52,578.44
48,496.85
43,885.68
38,654.49
33,498.14
32,837.50
29,065.91
26,415.54
31,308.14
28,108.61
27,392.01
Net Sales Growth
8.42%
10.51%
13.53%
15.39%
2.01%
12.98%
10.03%
-15.63%
11.38%
2.62%
 
Cost Of Goods Sold
10,747.36
10,662.61
10,662.16
10,351.54
8,690.08
9,230.45
7,868.97
7,351.71
8,164.20
6,170.19
6,732.84
Gross Profit
41,831.08
37,834.24
33,223.52
28,302.95
24,808.06
23,607.05
21,196.94
19,063.83
23,143.94
21,938.42
20,659.17
GP Margin
79.56%
78.01%
75.70%
73.22%
74.06%
71.89%
72.93%
72.17%
73.92%
78.05%
75.42%
Total Expenditure
37,726.08
35,747.77
32,298.12
28,772.68
25,030.42
25,863.35
22,792.27
20,880.73
21,625.92
19,950.29
19,615.54
Power & Fuel Cost
-
760.78
830.05
702.78
627.09
621.89
613.60
559.97
525.09
545.44
560.77
% Of Sales
-
1.57%
1.89%
1.82%
1.87%
1.89%
2.11%
2.12%
1.68%
1.94%
2.05%
Employee Cost
-
9,429.06
8,296.03
7,300.83
6,862.23
6,362.35
5,967.09
5,367.05
4,902.30
4,772.31
4,502.64
% Of Sales
-
19.44%
18.90%
18.89%
20.49%
19.38%
20.53%
20.32%
15.66%
16.98%
16.44%
Manufacturing Exp.
-
2,186.62
1,936.77
1,880.71
1,723.78
1,690.00
1,884.71
1,827.40
1,293.98
1,418.59
1,433.89
% Of Sales
-
4.51%
4.41%
4.87%
5.15%
5.15%
6.48%
6.92%
4.13%
5.05%
5.23%
General & Admin Exp.
-
5,252.93
4,256.12
3,270.55
3,179.45
3,340.89
2,729.20
2,862.45
3,113.67
2,956.85
2,894.97
% Of Sales
-
10.83%
9.70%
8.46%
9.49%
10.17%
9.39%
10.84%
9.95%
10.52%
10.57%
Selling & Distn. Exp.
-
5,780.26
5,226.24
4,096.33
3,103.96
3,654.48
2,621.13
1,864.55
2,520.64
2,262.35
2,236.40
% Of Sales
-
11.92%
11.91%
10.60%
9.27%
11.13%
9.02%
7.06%
8.05%
8.05%
8.16%
Miscellaneous Exp.
-
1,675.51
1,090.75
1,169.94
843.83
963.29
1,107.57
1,047.60
1,106.04
1,824.56
2,236.40
% Of Sales
-
3.45%
2.49%
3.03%
2.52%
2.93%
3.81%
3.97%
3.53%
6.49%
4.58%
EBITDA
14,852.36
12,749.08
11,587.56
9,881.81
8,467.72
6,974.15
6,273.64
5,534.81
9,682.22
8,158.32
7,776.47
EBITDA Margin
28.25%
26.29%
26.40%
25.56%
25.28%
21.24%
21.58%
20.95%
30.93%
29.02%
28.39%
Other Income
2,384.37
1,628.24
693.75
1,437.42
859.17
651.59
1,059.44
912.08
1,030.20
658.25
637.89
Interest
231.36
238.47
172.00
127.35
141.43
302.73
555.25
517.57
399.80
523.24
578.99
Depreciation
2,575.39
2,556.64
2,529.43
2,143.74
2,079.95
2,052.78
1,753.25
1,499.84
1,264.75
1,037.53
1,194.72
PBT
13,752.13
11,582.21
9,579.88
9,048.14
7,105.51
5,270.23
5,024.58
4,429.48
9,047.87
7,255.80
6,640.65
Tax
2,772.03
1,439.45
847.59
1,075.50
514.69
822.80
600.88
911.04
1,211.57
913.77
914.69
Tax Rate
20.16%
12.98%
9.01%
24.00%
18.39%
16.42%
15.77%
26.19%
13.39%
13.91%
14.29%
PAT
10,980.10
9,614.79
8,521.48
3,289.27
2,916.15
3,779.76
2,666.88
2,121.14
6,954.44
4,544.26
4,551.94
PAT before Minority Interest
10,944.39
9,648.44
8,560.84
3,405.82
2,284.68
4,186.79
3,209.32
2,567.94
7,836.30
5,656.86
5,488.21
Minority Interest
-35.71
-33.65
-39.36
-116.55
631.47
-407.03
-542.44
-446.80
-881.86
-1,112.60
-936.27
PAT Margin
20.88%
19.83%
19.42%
8.51%
8.71%
11.51%
9.18%
8.03%
22.21%
16.17%
16.62%
PAT Growth
13.80%
12.83%
159.07%
12.79%
-22.85%
41.73%
25.73%
-69.50%
53.04%
-0.17%
 
EPS
45.76
40.07
35.52
13.71
12.15
15.75
11.12
8.84
28.99
18.94
18.97

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
63,666.75
55,995.38
48,011.22
46,462.78
45,264.45
41,409.06
38,314.11
36,639.67
32,982.48
25,638.09
Share Capital
239.93
239.93
239.93
239.93
239.93
239.93
239.93
239.93
240.66
207.12
Total Reserves
63,426.82
55,755.45
47,771.29
46,222.85
45,024.52
41,169.13
38,074.18
36,397.10
32,736.26
25,374.38
Non-Current Liabilities
-2,731.14
-1,997.80
-1,316.37
-1,515.17
246.05
76.72
46.43
599.87
2,169.59
2,335.46
Secured Loans
0.00
0.00
0.00
7.83
6.18
109.47
217.69
185.59
7.73
40.69
Unsecured Loans
1.33
0.00
229.92
646.88
2,022.74
1,413.14
1,554.40
1,250.49
3,102.57
1,327.73
Long Term Provisions
413.89
342.91
369.07
327.12
511.00
430.39
404.46
1,211.11
1,895.86
2,532.34
Current Liabilities
16,983.77
19,906.38
17,208.45
16,145.63
15,706.43
17,339.62
19,864.32
17,887.02
13,143.96
16,146.81
Trade Payables
5,653.30
5,681.52
4,489.76
3,973.66
3,583.64
4,147.87
4,766.20
4,395.39
3,582.92
3,286.54
Other Current Liabilities
2,716.85
2,603.51
2,926.73
4,965.34
2,535.02
1,761.72
1,875.93
2,673.68
1,134.27
2,279.59
Short Term Borrowings
2,844.36
5,958.26
468.52
2,444.90
5,549.38
8,370.76
7,979.70
6,654.92
5,206.12
6,227.92
Short Term Provisions
5,769.26
5,663.09
9,323.44
4,761.73
4,038.39
3,059.27
5,242.49
4,163.03
3,220.65
4,352.76
Total Liabilities
81,358.60
77,224.05
66,958.19
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
Net Block
23,211.38
24,065.44
22,665.16
21,552.98
22,846.91
21,836.54
18,852.65
17,675.17
15,872.25
12,682.47
Gross Block
44,283.71
43,099.95
38,707.36
35,578.99
35,115.97
31,687.04
26,948.80
24,466.42
22,180.41
20,406.89
Accumulated Depreciation
21,072.33
19,034.51
16,042.20
14,026.01
12,269.06
9,850.50
8,096.15
6,791.25
6,308.16
7,724.42
Non Current Assets
37,884.25
37,341.33
32,093.59
33,668.21
33,423.01
31,069.75
30,473.12
25,963.77
22,439.98
18,055.80
Capital Work in Progress
5,353.88
4,973.16
1,286.80
1,566.83
1,220.34
1,411.15
2,465.16
2,801.38
2,175.45
2,038.61
Non Current Investment
6,441.23
5,451.73
5,214.65
6,482.39
5,245.75
3,951.81
3,052.25
961.00
1,116.07
598.87
Long Term Loans & Adv.
2,784.59
2,757.87
2,880.86
4,061.34
4,104.48
3,848.29
6,052.85
3,844.04
2,322.87
2,631.91
Other Non Current Assets
93.17
93.13
46.12
4.67
5.53
21.96
50.21
682.18
953.34
103.94
Current Assets
43,433.11
39,861.94
34,864.60
30,442.08
31,654.16
31,069.19
31,635.90
32,953.65
29,941.30
28,915.75
Current Investments
8,584.54
9,372.61
7,633.94
3,130.06
4,897.36
3,950.72
4,090.62
230.88
713.81
2,117.43
Inventories
9,868.29
10,513.05
8,925.13
8,997.02
7,874.99
7,885.98
6,880.69
6,832.81
6,422.54
5,667.99
Sundry Debtors
11,249.37
11,438.51
10,484.59
9,061.40
9,421.24
8,884.20
7,815.28
7,202.61
6,775.66
5,106.13
Cash & Bank
10,520.68
5,770.29
5,033.35
6,445.51
6,487.55
7,275.60
9,929.38
15,140.84
13,181.65
10,998.04
Other Current Assets
3,210.23
745.91
775.01
1,319.11
2,973.02
3,072.69
2,919.93
3,546.51
2,847.64
5,026.16
Short Term Loans & Adv.
2,454.24
2,021.57
2,012.58
1,488.98
1,431.54
1,806.39
2,028.62
2,828.26
2,317.13
1,920.52
Net Current Assets
26,449.34
19,955.56
17,656.15
14,296.45
15,947.73
13,729.57
11,771.58
15,066.63
16,797.34
12,768.94
Total Assets
81,317.36
77,203.27
66,958.19
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
12,134.98
4,959.33
8,984.54
6,170.37
6,554.77
2,196.45
3,907.15
7,082.21
6,685.86
5,615.74
PBT
11,087.89
9,408.43
4,481.32
2,799.37
5,009.59
3,810.20
3,478.98
9,047.87
6,570.63
6,402.90
Adjustment
1,554.40
2,722.56
1,974.95
1,809.85
1,992.54
1,968.66
1,382.22
500.67
1,856.92
773.61
Changes in Working Capital
1,062.13
-5,661.82
1,559.05
2,564.09
898.55
-2,696.00
-212.31
-409.21
246.77
179.59
Cash after chg. in Working capital
13,704.42
6,469.17
8,015.32
7,173.31
7,900.68
3,082.86
4,648.89
9,139.33
8,674.32
7,356.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,569.44
-1,509.84
969.22
-1,002.94
-1,345.91
-886.41
-741.74
-2,057.12
-1,988.46
-1,740.36
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-690.20
-7,943.68
-5,724.74
536.22
-2,588.84
-681.25
-3,370.81
-4,221.60
-4,371.59
-2,865.74
Net Fixed Assets
-420.26
-573.97
-1,120.95
-8,061.35
-737.44
-543.38
-1,471.92
-1,217.15
2,214.23
-4,631.67
Net Investments
183.27
2,935.63
-11.67
1,824.52
542.39
451.15
978.04
3,038.39
3,504.47
-18,860.43
Others
-453.21
-10,305.34
-4,592.12
6,773.05
-2,393.79
-589.02
-2,876.93
-6,042.84
-10,090.29
20,626.36
Cash from Financing Activity
-6,710.16
2,376.07
-5,193.46
-5,980.48
-5,715.14
-2,730.52
-1,539.26
-2,285.39
-1,888.53
-1,186.53
Net Cash Inflow / Outflow
4,734.62
-608.28
-1,933.66
726.11
-1,749.21
-1,215.32
-1,002.92
575.22
425.74
1,563.47
Opening Cash & Equivalents
4,623.73
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,183.49
4,358.70
Closing Cash & Equivalent
9,285.65
4,623.73
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,285.56

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
265.36
233.38
200.11
193.65
188.66
172.59
159.69
152.70
137.03
123.49
ROA
12.17%
11.88%
5.20%
3.54%
6.58%
5.17%
4.24%
0.00%
11.39%
14.60%
ROE
16.13%
16.46%
7.21%
4.98%
9.66%
8.05%
6.85%
0.00%
19.32%
24.89%
ROCE
17.60%
17.24%
9.28%
5.68%
10.07%
8.68%
8.40%
0.00%
18.64%
25.06%
Fixed Asset Turnover
1.11
1.07
1.81
1.74
1.78
1.92
1.99
1.29
1.34
1.79
Receivable days
85.38
91.17
53.09
54.88
56.22
54.10
53.53
83.25
76.12
48.20
Inventory Days
76.70
80.83
48.68
50.10
48.40
47.84
48.88
78.98
77.46
57.99
Payable days
194.01
174.10
149.21
158.71
152.86
77.81
90.19
85.47
75.24
52.05
Cash Conversion Cycle
-31.93
-2.10
-47.44
-53.73
-48.24
24.13
12.23
76.75
78.34
54.14
Total Debt/Equity
0.04
0.11
0.02
0.08
0.18
0.25
0.27
0.27
0.26
0.35
Interest Cover
47.50
55.70
36.19
20.79
17.55
7.86
7.72
23.63
13.56
12.06

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Sun Pharma’s partner withdraws application for marketing authorization to EMA for Nidlegy
    25th Jun 2025, 12:10 PM

    Sun Pharmaceutical Industries’ partner Philogen S.p.A has voluntarily withdrawn the application for marketing authorization to the European Medicines Agency for Nidlegy

    Read More
  • USFDA conducts GMP inspection of Sun Pharma’s Halol facility
    14th Jun 2025, 10:09 AM

    At the conclusion of the inspection, the USFDA issued a Form-483, with 8 observations

    Read More
  • Sun Pharmaceutical Industries to invest up to $25 milion in Pharmazz Inc
    26th May 2025, 10:23 AM

    The company has entered into an agreement with US based Pharmazz Inc

    Read More
  • Sun Pharmaceutical Industries reports 19% fall in Q4 consolidated net profit
    23rd May 2025, 16:14 PM

    The total consolidated income of the company increased by 7.81% at Rs 13571.71 crore for Q4FY25

    Read More
  • Sun Pharmaceutical Industries’ arm recalls around 13,700 bottles of Gabapentin capsules
    14th Apr 2025, 11:43 AM

    Sun Pharmaceutical Industries Inc is recalling the affected lot due to 'Cross Contamination'

    Read More
  • US court lifts restrictions on Sun Pharma launching autoimmune disorder drug
    11th Apr 2025, 11:53 AM

    While the litigation between Incyte Corporation and the company continues, the preliminary injunction is no longer in effect

    Read More
  • Sun Pharma launches Fexuprazan tablets 40 mg in India
    7th Apr 2025, 10:47 AM

    The company has obtained rights from Daewoong Pharmaceutical Co, Korea to manufacture and commercialise FEXUCLUE (Fexuprazan) in India

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.